2017
Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease
Samad Z, Sivak JA, Phelan M, Schulte PJ, Patel U, Velazquez EJ. Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease. Journal Of The American Heart Association 2017, 6: e006044. PMID: 29021274, PMCID: PMC5721834, DOI: 10.1161/jaha.117.006044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAortic ValveAortic Valve StenosisComorbidityDatabases, FactualEchocardiographyFemaleGlomerular Filtration RateHumansKaplan-Meier EstimateKidneyMaleMiddle AgedMitral ValveMitral Valve InsufficiencyNorth CarolinaPrevalencePrognosisProportional Hazards ModelsRenal Insufficiency, ChronicRetrospective StudiesRisk FactorsSeverity of Illness IndexSex FactorsTime FactorsConceptsChronic kidney diseaseFive-year survival estimatesNon-CKD patientsCKD patientsMitral regurgitationMR severityKidney diseaseSurvival estimatesCoronary artery bypassGlomerular filtration ratePercutaneous coronary interventionSevere mitral regurgitationValvular heart diseaseSerum creatinine valuesAdverse prognostic markerRegurgitant valve lesionsIndex echocardiogramSevere ASArtery bypassIntervention patientsValve lesionsValve surgeryCoronary interventionHazard ratioHeart failure
2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, investigators F. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 2010, 375: 1173-1181. PMID: 20170948, DOI: 10.1016/s0140-6736(09)62100-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlbuminuriaAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCardiovascular DiseasesCreatinineDisease ProgressionDiureticsDouble-Blind MethodDrug CombinationsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionKidney Failure, ChronicMaleMiddle AgedRisk FactorsConceptsChronic kidney diseaseKidney diseaseAmlodipine groupHydrochlorothiazide groupCardiovascular eventsCombination therapyHigh riskChronic kidney disease progressionEnd-stage renal diseaseFixed-dose combination therapyAvoiding Cardiovascular EventsBlood pressure goalsInitial antihypertensive therapyInitial antihypertensive treatmentPrespecified secondary analysisProgression of nephropathySystolic Hypertension (ACCOMPLISH) trialFrequent adverse eventsKidney disease progressionSerum creatinine concentrationTelephone-based interactive voice response systemAntihypertensive therapyAntihypertensive treatmentRenal outcomesCardiovascular morbidity